drugset / Trial / NCT04379713

20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants

NCT04379713

Phase 3 Completed 1511 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study is designed to evaluate the safety and tolerability of 20vPnC in healthy infants.

Timeline

Start
2020-05-21
Primary completion
2022-08-31
Completion
2022-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject 20-valent pneumococcal conjugate vaccine Vaccine
Comparator Prevnar 13 Vaccine